LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Akciju saraksts・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Slēgts

SektorsVeselības aprūpe

177.75 -1.7

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

177.11

Max

179.91

Galvenie mērījumi
By Trading Economics
Ienākumi	-332M -277M
Pārdošana	-11M 994M
Peļņas marža	-27.816
Darbinieki	18,300
EBITDA	730K 198M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+13.68% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	562M 8.5B
Iepriekšējā atvēršanas cena	179.45
Iepriekšējā slēgšanas cena	177.75

Ziņu noskaņojums

By Acuity

41%

59%

156 / 347 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

117.16 / 144.77 Atbalsts un pretestība

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 8. maijs 23:55 UTC

Peļņas

Review & Preview: Still Going Strong -- Barrons.com

2026. g. 8. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 8. maijs 20:49 UTC

Peļņas

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

2026. g. 8. maijs 20:25 UTC

Peļņas

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026. g. 8. maijs 19:43 UTC

Peļņas

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

2026. g. 8. maijs 19:43 UTC

Peļņas

Cencosud 1Q Net $115M

2026. g. 8. maijs 19:20 UTC

Tirgus saruna

Oil Futures End Session Higher, But Down on the Week -- Market Talk

2026. g. 8. maijs 19:18 UTC

Peļņas

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

2026. g. 8. maijs 19:16 UTC

Peļņas

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026. g. 8. maijs 19:08 UTC

Peļņas

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026. g. 8. maijs 19:05 UTC

Peļņas

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

2026. g. 8. maijs 19:02 UTC

Tirgus saruna

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

2026. g. 8. maijs 18:51 UTC

Peļņas

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

2026. g. 8. maijs 18:49 UTC

Peļņas

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026. g. 8. maijs 18:41 UTC

Peļņas

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

2026. g. 8. maijs 17:38 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

2026. g. 8. maijs 17:14 UTC

Peļņas

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

2026. g. 8. maijs 17:04 UTC

Tirgus saruna

Zcash Caps Off Parabolic Week -- Market Talk

2026. g. 8. maijs 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 8. maijs 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 8. maijs 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 8. maijs 15:39 UTC

Tirgus saruna

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

2026. g. 8. maijs 15:39 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 8. maijs 15:39 UTC

Tirgus saruna

Canada's Job Market Sees Worst Start in Years -- Market Talk

2026. g. 8. maijs 15:36 UTC

Tirgus saruna

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

2026. g. 8. maijs 15:20 UTC

Tirgus saruna

'Altcoin Season' Indicator on the Rise -- Market Talk

2026. g. 8. maijs 15:20 UTC

Tirgus saruna

Peļņas

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

2026. g. 8. maijs 15:05 UTC

Tirgus saruna

Bitcoin Slips Back Below the $80k Mark -- Market Talk

2026. g. 8. maijs 14:42 UTC

Tirgus saruna

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

2026. g. 8. maijs 14:39 UTC

Tirgus saruna

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

13.68% augšup

Prognoze 12 mēnešiem

Vidējais 201.91 USD 13.68%

Augstākais 235 USD

Zemākais 160 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

117.16 / 144.77Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

156 / 347 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.